Proteinuria is one of the well-known risk factors for cardiovascular disease. However the impact of proteinuria on the incidence of atrial fibrillation (AF) is unclear. In this study, we investigated the association between proteinuria detected using urine dipstick test and the risk of AF. A total of 18,201,275 individuals were analyzed, who had no prior AF and had received biennial health checkups provided by the National Health Insurance Service between 2005 and 2008 in Korea. Incidences of AF were ascertained through the end of 2015. During a mean follow-up of 9.6 years, a total of 324,764 (1.8%) developed AF (1.86 per 1,000 person-years). In Cox regression models, proteinuria was associated with an increased risk of AF: adjusted HR and 95% CI of AF occurrence were 1.13 (1.10-1.16), 1.34 (1.31-1.38), 1.53 (1.48-1.58), 1.82 (1.71-1.94), and 1.86 (1.61-2.16) in individuals with trace, 1+, 2+, 3+, and 4+ proteinuria, respectively, compared with those without proteinuria. The result was consistent even after additional adjustment for estimated glomerular filtration rate. In addition, the risk of AF further increased or decreased according to the follow-up dipstick test results. Thus, proteinuria measured with a dipstick test might be considered a potent risk factor for AF development.
Results
The baseline characteristics of the study cohort by categories of dipstick proteinuria are summarized in Table 1 . The mean age of study population was 45.3 ± 14.6 years and 53.3% were male. Among a total of 18,201,275 study subjects, dipstick urinalysis showed negative protein in 96.76% (n = 17,611,940), trace in 1.49% (n = 270,707), 1+ in 1.18% (n = 214,883), 2+ in 0.46% (n = 83,251), 3+ in 0.10% (n = 17,386), and 4+ in 0.02% (n = 3,108). Subjects with a higher degree of proteinuria were more likely to be older, overweight, with a higher frequency of hypertension, diabetes, dyslipidemia, ischemic heart disease, myocardial infarction, congestive heart failure, stroke, and chronic obstructive lung disease. During 9.6 ± 1.9 years of follow-up, 324,764 individuals (1.8% of the total population) developed AF. The median time to AF development was 5.3 years. Unadjusted risk factors for AF are presented in Table 2 . Both traditional risk factors and proteinuria demonstrated a relationship with AF development, and the degree of proteinuria was shown to be strongly correlated with the risk of AF development.
Proteinuria on dipstick test as an independent risk factor for atrial fibrillation. Figure 1 shows Kaplan-Meier survival curves of freedom from AF for up to 11 years according to the degree of proteinuria detected by dipstick test. The annual incidence rate of AF was 1.8 per 1,000 person-years for the negative proteinuria group, 2.5 for the trace proteinuria group, 3.6 for the 1+, 4.7 for the 2+, 6.1 for the 3+, and 6.8 for the 4+ group, respectively. Higher levels of proteinuria were associated with a higher risk of AF development (p for trend < 0.001). The incidence rate of AF in subjects with proteinuria 4+ was approximately two times higher compared to that in subjects with negative proteinuria (HR 2.05, 95% CI 1.77-2.37, p < 0.001) after adjusting for age, sex, body mass index, smoking, alcohol consumption, exercise frequency, hypertension, diabetes, and dyslipidemia (Table 3 , model 3). The HRs were only slightly attenuated after additional adjustment for ischemic heart disease, congestive heart failure, stroke, and chronic obstructive pulmonary disease (HR 1.86, 95% CI 1.61-2.16, p < 0.001, Table 3 , model 4). A proportional increase in the risk of AF with the level of proteinuria was consistent regardless of age groups, sex, hypertension, diabetes mellitus, and chronic kidney disease (Fig. 2 ).
Proteinuria on dipstick and graded risk of AF after adjustment of kidney function. To adjust
the impact of kidney function on the risk of AF, a sensitivity analysis was performed using the Follow-up Cohort which included data on serum creatinine levels. eGFR was calculated using the Cockcroft-Gault equation and added to the multivariable analysis. After adjustment for potential confounders including eGFR, there was a graded risk of AF according to the severity of dipstick proteinuria (p for trend < 0.001, Table 4 , model 5). The positive correlation between AF risk and the degree of dipstick proteinuria was consistent across all three categories of eGFR (<30 mL/min, 30~60 mL/min, and ≥ 60 mL/min,). The association between the grade of proteinuria and AF risk was strongest in the group with eGFR < 30 mL/min compared with other groups (Fig. 3 ).
Change in proteinuria on dipstick and risk of AF. We sought to determine whether there is difference in the risk of AF according to the change in the dipstick test results over time, using the Follow-up Cohort. Among individuals who had undergone more than two dipstick tests, two test results were selected that were at least four years apart. Most subjects (n = 14,126,994, 92.8%) who showed initially negative dipstick results were still negative on subsequent tests. However, in those with trace or positive results during the follow-up period, the risk of Table 2 . Age and sex-adjusted hazard ratios for the risk of atrial fibrillation. COPD, chronic obstructive pulmonary disease; CI, confidence intervals; HR, hazard ratio; MI, myocardial infarction AF increased significantly after adjustment for covariates ( Table 5 ). Among those whose proteinuria progressively increased, the risk of AF increased by nearly 40% (negative to≥1+, HR 1.36, 95% CI 1.33-1.39; trace to ≥1+, HR 1.38, 95% CI 1.25-1.52). In contrast, in subjects whose proteinuria was resolved, the risk of AF decreased significantly. In subjects who showed trace results at baseline and a negative result on the follow-up test, there was no significant change in the risk of AF compared to those whose levels remained trace on the follow-up test (HR 1.06, 95% CI 1.02-1.10; HR 1.09, 95% CI 0.94-1.27). However, in those with greater than 1+ levels of proteinuria at baseline and a negative result on the follow-up test, the risk of AF decreased compared to those who remained at the same level (HR 1.15, 95% CI 1.10-1.19 vs. HR 1.69, 95% CI 1.61-1.77).
Discussion
To the best of our knowledge, this is the largest population-based study to examine the impact of the proteinuria dipstick test on the risk of AF. The present study demonstrated the following findings: (1) Proteinuria detected using a dipstick test was significantly associated with an increased risk of AF development; (2) there was a graded risk of AF according to the severity of dipstick proteinuria; (3) dipstick proteinuria was an independent risk factor for AF, even after accounting for potential confounders, including GFR; and (4) the risk of AF increased or decreased according to the results of the follow-up dipstick test. Proteinuria, particularly microalbuminuria, can be observed in the absence of any evident renal disease and earlier than any apparent decline in GFR, even in the nondiabetic and non-hypertensive population 18 . In such cases, urinary protein excretion reflects not only subclinical renal disease, but also generalized endothelial dysfunction 19, 20 . Moreover, proteinuria is more frequent in patients with diabetes mellitus, high blood pressure, and diseases that cause chronic inflammation, all of which are established risk factors for AF [21] [22] [23] . In addition, several studies recently reported that AF is closely associated with the presence of proteinuria 11, [24] [25] [26] . Therefore, proteinuria may indeed serve as a sentinel marker for AF risk. It is generally recommended to measure ACR or PCR in "spot" urine samples to quantify and qualify the degree of proteinuria 27 . The urine dipstick test has a high sensitivity and specificity in screening proteinuria when compared with PCR or ACR. An Australian cohort study reported that a dipstick result of at least 1+ or greater identified ACR≥300 mg/g with 98.9% sensitivity and 92.6% specificity 12 . In the Korean elderly population, a cutoff value of 1+ also exhibited a high sensitivity and specificity (95.6% and 92.2%, respectively) in detecting ACR ≥300 mg/g and PCR 0.5 g/g (sensitivity, 95.6%; specificity, 86.9%) 13 . Therefore, dipstick proteinuria of 1+ or greater can reliably identify significant proteinuria. Although a dipstick test could detect proteinuria with a high sensitivity and specificity, it could generate unacceptable false-positive rates in population-based screening since the prevalence of significant proteinuria is low in the general population 28 . Furthermore, the grading of proteinuria is only semi-quantitative and dependent on urine concentration. A dipstick result of 1+ refers to Table 5 . Risk of atrial fibrillation according to the follow-up dipstick test. AF, atrial fibrillation; CI, confidence intervals; HR, hazard ratios. Model 1 to 5: Cox proportional models as in Table 4 . Covariates adjusted in these models were acquired at the time of the secondary dipstick urine tests. *In model 5, estimated glomerular filtration rate was calculated based on the follow-up health checkup data. approximately 30 mg of protein per dL; 2+ refers to 100 mg/dL; 3+ to 300 mg/dL, and 4+ to 1,000 mg/dL 29 . Nonetheless, the urine dipstick test is still recommended as an initial test for the evaluation of CKD 27 and is widely used, particularly in population-based health screening, due to its simplicity and low-cost 30, 31 . In this study, proteinuria on dipstick test, conducted in a context of population-based screening, was proven to be a strong risk factor for AF development. CKD is a well-known risk factor for cardiovascular disease 32 , reduced kidney function is associated with increased risk of not only coronary heart disease, heart failure, and mortality, but also AF 11, 33, 34 . Lower eGFR was reported to be associated with incident AF even within the normal or mildly impaired range 35 . Since proteinuria is a primary marker of kidney damage and is associated with poorer outcomes in CKD patients, it is difficult to elucidate the impact of proteinuria on the development of AF. In our study, after adjusting for kidney function either by inclusion of eGFR as a covariate or by subgroup analysis according to the presence of CKD, we found that proteinuria is in fact an independent risk factor for AF development.
Proteinuria itself is also a risk factor for cardiovascular outcomes, independently of conventional risk factors including CKD [6] [7] [8] [9] . The Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL) study showed the renal protective effect of losartan in patients with diabetic nephropathy, which resulted in the reduction of proteinuria and an improvement in cardiovascular outcomes 36 . Although we do not have a definite explanation regarding how proteinuria has decreased in our study, we found that the decrease in proteinuria between serial dipstick tests was associated with the reduction in AF risk in the general population. Interestingly, in individuals whose proteinuria had progressed from negative to ≥1+, the risk of AF increased by approximately 40%. Proteinuria on dipstick test was shown to be an independent risk factor for AF development. However, it was also found to be a modifiable risk factor for AF development.
Our study has several limitations. First, this study is a nationwide population-based retrospective observational study, which is susceptible to several biases including selection bias. The NHIS provides biennial health checkups to all health insurance subscribers, but only half of the subjects actually received these medical examinations. Therefore, the study population most likely included those who maintain healthier lifestyles, or those who are more concerned about their health. Second, the incidence of AF was based entirely on claim data and there could have been undetected or unreported incidences of AF. There is an inherent possibility of underestimation of silent AF because population studies using claim data do not, by nature, screen subjects directly with ECG. Conversely, misclassification of AF diagnostic codes could lead to overestimation of AF. Frequent and long-term monitoring is reported to improve the detection rate of AF 37, 38 . Third, a baseline urine dipstick protein was obtained by a single measurement. This may lead to random measurement error and regression dilution bias 39, 40 , which tends to underestimate the real association between proteinuria and AF development. Since dipstick urinalysis is a semi-quantitative test, it has its own variability. Changes in the level of proteinuria during the follow-up may also dilute the impact of proteinuria on the risk of AF development. Although we did not correct the regression dilution bias directly, we assessed the risk of AF development according to the change in dipstick proteinuria over time, which showed that the risk of AF development increased by approximately 40% among those whose proteinuria grade increased. Fourth, in the current study, data regarding prescription medication use were not available. Studies have shown that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) reduce proteinuria and protect against deterioration in renal function in patients with diabetic nephropathy 41 . ACEIs and ARBs are also known to prevent new-onset AF 42 . Thus, data on prescription medications, especially ACEIs and ARBs, would have enriched our results. Fifth, this study was composed of an entirely Korean population. Therefore, the results may not be generalizable to other ethnicities. Lastly, the self-reported questionnaires might have a limited quality of information and lack verification.
In conclusion, we found that proteinuria detected by urine dipstick test is a potent risk factor for AF development. There was graded risk of AF according to the severity of dipstick proteinuria. Moreover, the risk of AF was shown to decrease or increase according to the results of follow-up dipstick tests. The urine dipstick test could be a simple and easy way to predict the risk of AF in the general population. However, further investigations are needed to determine whether dipstick test screening could be used as a method to stratify individuals at risk of AF who require more intensive monitoring and stroke prevention.
